Kevin Patrick Moran - 02 Mar 2026 Form 4 Insider Report for Vanda Pharmaceuticals Inc. (VNDA)

Reporting relationship: SVP, CFO & Treasurer
Issuer ticker: VNDA
Reported as of: 02 Mar 2026
Net transaction value: -$350,821
SEC form: 4
Accepted by SEC: 04 Mar 2026, 18:53:14 UTC
Prior SEC filing: 19 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Kevin Patrick Moran

Key filing fact

Kevin Patrick Moran filed Form 4 for Vanda Pharmaceuticals Inc. (VNDA) on 04 Mar 2026.

Key facts

This page summarizes Kevin Patrick Moran's Form 4 filing for Vanda Pharmaceuticals Inc. (VNDA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 04 Mar 2026, 18:53.

Change

Previous filing in this sequence was filed on 19 Feb 2026.
Current net transaction value: -$350,821.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001806596 Primary reporting owner

Moran Kevin Patrick

Relationship: SVP, CFO & Treasurer
Address: 2200 PENNSYLVANIA AVENUE NW, SUITE 300E, WASHINGTON
Signature: /s/ Kevin Patrick Moran
Signature date: 04 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VNDA transaction

Common Stock

Sale

Transaction value: $350,821
Shares: -42,442
Change %: -9.4%
Price: $8.27
Shares after: 411,380
Date: 02 Mar 2026
Ownership: Direct
Footnotes: F1, F2

VNDA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 635
Date: 02 Mar 2026
Ownership: By Wife

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents shares of the Issuer's common stock sold to satisfy tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the settlement of the vested portion of RSUs. Such sale was executed pursuant to the withholding tax provisions of the RSU agreements.

Footnote F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.085 to $8.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.